Vigil Neuroscience, Inc. VIGL 深 沪
等待开盘 08-16 09:30:00 美东时间
8.05
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 8.05
- 总市值 3.76亿
- 52周最高 8.10
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.312
- 委 比 0.00%
- 总股本 4667.15万
- 历史最高 18.27
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.312
- 每 手 1
- 风险率 2.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vigil Neuroscience Q2 EPS $(0.56) Misses $(0.42) Estimate
Vigil Neuroscience (NASDAQ:VIGL) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.42) by 32.08 percent. This is a 7.69 percent decrease over losses of $(0.52) per share
08-05 21:37
Vigil Neuroscience Inc Merger and Leadership Changes
An update from Vigil Neuroscience Inc ( ($VIGL) ) is now available. On August 4...
08-05 21:28
Vigil Neuroscience Faces Stockholder Demands Post-Merger
Vigil Neuroscience Inc ( ($VIGL) ) has issued an update. On May 21, 2025, Vigil...
07-28 19:57
Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel
Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease progression and cognitive decline.
07-25 21:27
Vigil Neuroscience Awaits HSR Expiration for Sanofi Merger
Vigil Neuroscience Inc ( ($VIGL) ) has shared an announcement. On May 21, 2025,...
07-17 19:27
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: TASK, VIGL, STRM, and CHTR
NEW YORK, July 3, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders...
07-04 05:34
Vigil Neuroscience Announces Special Meeting for Sanofi Merger Vote
New activity is brewing for Vigil Neuroscience Inc ( ($VIGL) ). The company has...
06-30 23:56
Why InMed's Alzheimer's Drug Candidate Is Fueling Sudden Stock Surge
InMed stock jumped after preclinical data showed INM-901 lowered brain inflammation tied to Alzheimer's and improved cognitive function in models.
06-24 21:01
Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib
NewAmsterdam shared new Phase 3 data showing obicetrapib reduced LDL-C by 33% and impacted Alzheimer's biomarkers ahead of July 2025 presentation.
06-10 00:23
Vigil Neuroscience fails in mid-stage study for lead asset
Vigil Neuroscience (NASDAQ:VIGL) announced on Wednesday that a mid-stage trial for its lead candidate, iluzanebart, didn’t succeed in patients with a rare neurological disease called adult-onset leuko...
06-04 19:26
